Acumen Pharmaceuticals, Inc. Common Stock ABOS
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-11T13:50:28.687Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T13:49:16.688481394Z
FundamentalsAlpha Vantage · ready · quarter 2026-09-30 · fetched 2026-11-11T13:50:27.700431+00:00
Acumen Pharmaceuticals, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 7.27 | 587.3% | 3002.7% | 0.53 | 772.7% | 94.6% |
| 25Δ | 3.87 | 419.3% | 1557.7% | 0.57 | 736.0% | 87.4% |
| 30Δ | 0.60 | 699.3% | 80.2% | |||
| 35Δ | 0.64 | 662.7% | 73.0% | |||
| 40Δ | 0.68 | 626.0% | 65.8% | |||
| 45Δ | 0.72 | 589.3% | 58.6% | |||
| 50Δ | 0.75 | 552.7% | 51.4% | |||
| 55Δ | 0.79 | 516.0% | 44.2% | |||
| 60Δ | 0.83 | 479.3% | 37.0% | |||
| 65Δ | 0.87 | 442.7% | 29.8% | |||
| 70Δ | ||||||
| 75Δ | ||||||
| 80Δ | ||||||
20Δ
- Pseudo strike
- 7.27
- IV
- 587.3%
- B/E move
- 3002.7%
- Pseudo strike
- 0.53
- IV
- 772.7%
- B/E move
- 94.6%
25Δ
- Pseudo strike
- 3.87
- IV
- 419.3%
- B/E move
- 1557.7%
- Pseudo strike
- 0.57
- IV
- 736.0%
- B/E move
- 87.4%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.60
- IV
- 699.3%
- B/E move
- 80.2%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.64
- IV
- 662.7%
- B/E move
- 73.0%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.68
- IV
- 626.0%
- B/E move
- 65.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.72
- IV
- 589.3%
- B/E move
- 58.6%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.75
- IV
- 552.7%
- B/E move
- 51.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.79
- IV
- 516.0%
- B/E move
- 44.2%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.83
- IV
- 479.3%
- B/E move
- 37.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 0.87
- IV
- 442.7%
- B/E move
- 29.8%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
Options history
No recorded observations
Biotechnology
ABSI
Absci Corp (ABSI) is a cutting-edge biotechnology company that utilizes a proprietary AI-driven platform to revolutionize drug discovery and development. By facilitating the rapid…
More →ABUS
Description unavailable
More →ABVX
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is in…
More →ACAD
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central…
More →ACET
Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company is headquartered in Boston,…
More →ACHV
Description unavailable
More →